Similar efficacy of nitrendipine in young and elderly hypertensive patients. 1987

J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
Department of Medicine and Pharmacy Practice, University of Florida, Gainesville.

Calcium channel blockers have been postulated to be more effective as monotherapeutic antihypertensive agents in the elderly than in younger patients. To determine if a new dihydropyridine derivative, nitrendipine, is more effective in the elderly (older than 60 years) than in younger hypertensive subjects (younger than 60 years), nitrendipine was administered in a multicentered study to 21 elderly and 33 younger subjects with essential hypertension. After gradual discontinuation of previous antihypertensive therapy and 2 weeks of placebo, the daily dose of nitrendipine (10 to 40 mg) was titrated over 3 weeks to achieve a 10 mm Hg decrease in supine diastolic blood pressure (BP) for patients entering with 90 to 99 mm Hg. For patients entering with at least 100 mm Hg, the dose was titrated to diastolic BP no greater than 90 mm Hg. Titrated dose of nitrendipine was maintained for 4 additional weeks. Propranolol was added for "symptomatic" tachycardia. Nitrendipine reduced BP in 90% of patients completing all phases of the study (n = 49). The proportion of responders was 47% among the elderly and 44% among young subjects. Change in heart rate was similar in both groups (-0.1 +/- 9.9 and +2.9 +/- 8.8 beats/min, mean +/- standard deviation). Two elderly and 1 younger subject required addition of propranolol (difference not significant). There was no correlation between the age of patients and changes in supine systolic and diastolic BP or heart rate (r = 0.21, -0.15 and -0.21, respectively). Adverse effects occurred with equal frequency in older and younger subjects (19 of 21 vs 23 of 33 patients, difference not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009568 Nitrendipine A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. Balminil,Bay e 5009,Bayotensin,Baypresol,Baypress,Gericin,Jutapress,Nidrel,Niprina,Nitre AbZ,Nitre-Puren,Nitregamma,Nitren 1A Pharma,Nitren Lich,Nitren acis,Nitrend KSK,Nitrendepat,Nitrendi Biochemie,Nitrendidoc,Nitrendimerck,Nitrendipin AL,Nitrendipin Apogepha,Nitrendipin Atid,Nitrendipin Basics,Nitrendipin Heumann,Nitrendipin Jenapharm,Nitrendipin Lindo,Nitrendipin Stada,Nitrendipin beta,Nitrendipin-ratiopharm,Nitrendipino Bayvit,Nitrendipino Ratiopharm,Nitrensal,Nitrepress,Tensogradal,Trendinol,Vastensium,nitrendipin von ct,nitrendipin-corax,Nitre Puren,NitrePuren,Nitrendipin ratiopharm,Nitrendipinratiopharm,nitrendipin corax,nitrendipincorax
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
January 1993, Clinical and experimental hypertension (New York, N.Y. : 1993),
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
September 1990, Revista clinica espanola,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
September 1988, British journal of clinical pharmacology,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
January 1989, Journal of cardiovascular pharmacology,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
April 1990, Journal of human hypertension,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
January 1991, Journal of cardiovascular pharmacology,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
January 1989, Journal of cardiovascular pharmacology,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
July 1986, Fortschritte der Medizin,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
January 1992, European journal of clinical pharmacology,
J Mehta, and L M Lopez, and P C Deedwania, and T C Fagan, and C M Sternlieb, and N D Vlachakis, and J P Birkett, and L A Schwartz
July 1988, Archives of internal medicine,
Copied contents to your clipboard!